CD274 and neoplasm: The use of PD-1 inhibitors or PD-L1 inhibitors to sensitize tumor therapy can reverse this evasion, enhancing anti-tumor immune activity, and the FDA has approved PD-L1 inhibitors such as Atezolizumab, Durvalumab, and Avelumab for use in cancer therapy [4].